{
  "name" : "twin.sci-hub.se_6295_6ef5968597415a07f4b4e801f419fe9d_abd-rabou2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "CS-PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line",
    "authors" : [ "Ahmed A. Abd-Rabou", "Hanaa H. Ahmed" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "12\n3\n4\n5\n6 Q1\n7\n8 9\n10 11 12 13 14 15 16 17 18 19\nAdvances in Medical Sciences xxx (2017) xxx–xxx\nQ2\nOriginal research article\nCS-PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line\nAhmed A. Abd-Rabou , Hanaa H. Ahmed *\nHormones Department, Medical Research Division, National Research Centre, Dokki, 12622 Giza, Egypt\nA R T I C L E I N F O\nArticle history: Received 14 October 2016 Accepted 10 January 2017 Available online xxx\nKeywords: PLGA-CS-PEG nanoparticles HepG2 cell line Phytochemicals Apoptosis\nA B S T R A C T\nPurpose: Polymer-based nanoparticles are used as vectors for cancer drug delivery. The bioactive compounds (quercetin, ellagic acid and gallic acid) are well known to be not only antioxidants but also chemopreventive candidates against various types of cancers. To circumvent the low bioavailability and the short half-life time obstacles, we hypothesized a novel PLGA nano-platform functionalized with CS and PEG to encapsulate these phytochemicals. This encapsulation will protect the compounds from the phagocytic uptake and deliver PLGA-CS-PEG nano-prototype with high biodegradability and biosafety. Materials and methods: Three consequent types of PLGA-based nanocomposites were prepared and characterized. Furthermore, we investigated the newly synthesized nano-formulations against human hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cell lines using cell growth inhibition assays, followed by apoptosis and necrosis assays using flow cytometry to detect the underlying mechanism of HepG2 cell death. Results: Through Malvern Zeta Sizer, we recorded that the average diameters of the nano-prototypes ranged from 150 to 300 nm. Regarding the cytotoxic activity of quercetin, ellagic acid, and gallic acidencapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes has been found that they reduce the IC50s of the HepG2 cells values by 2.2, 2.9, 2.8-folds, 1, 1.5, 2.7-folds, and 0.9, 0.7, 1.5-folds, respectively. Mechanistically, the nano-platforms of quercetin seem to be dependent on both apoptosis and necrosis, while those of ellagic acid and gallic acid are mainly dependent on apoptosis. Conclusions: CS-PEG-blended PLGA nano-delivery system of quercetin, ellagic acid and gallic acid can potentiate apoptosis-mediated cell death in HepG2 cell line.\n2017 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.\nContents lists available at ScienceDirect\nAdvances in Medical Sciences\njo u rn al ho m epag e: ww w.els evier .c o m/lo cat e/advm s\n20 21 22 23 24 25 26 27 28 29 30 31"
    }, {
      "heading" : "1. Introduction",
      "text" : "Hydrolyzed tannins, ellagitannins (ETs) and gallotannins (GTs), are considered to be the most bioactive polyphenols of pomegranates [1–5]. Due to ETs and GTs are naturally unstable agents, they are hydrolyzed to ellagic acid and gallic acid, respectively [6–8]. ET and GT moieties enhance cancer apoptosis and reduce proliferation, metastasis, and inflammation in various cancer cell lines [9–14], including hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cell lines [15]. In addition, authors observed that nanoparticles of these moieties had a 2- to 12-fold\n32 33 34 35 36 * Corresponding author. Fax: +20 2 33370931. E-mail addresses: ahmedchemia87@yahoo.com (A.A. Abd-Rabou),\nhanaaomr@yahoo.com (H.H. Ahmed).\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003\nhttp://dx.doi.org/10.1016/j.advms.2017.01.003 1896-1126/ 2017 Medical University of Bialystok. Published by Elsevier B.V. All right\nenhanced impact on cell proliferation inhibition compared to their free forms upon breast (MCF-7 and Hs578T) cancer cells [13].\nMoreover, pre-clinical [16–18] and phase II clinical trials [19,20] suggested that those pomegranate compounds suppressed the progression of human tumorigenesis in cancer-induced mouse models. In vivo, ETs reduced the occurrence of chemically inducedlung cancer, reduced the volume and metastatic capacity of estrogen-induced breast cancers, and elicited cancer cell apoptosis [12–29]. These findings verified that these phytochemicals offer defense against several cancer-relevant processes [15,30,31].\nAlthough the bioactive properties of ETs and GTs, their low bioavailability and short retention time may challenge their anticancer prospective. For instance, ETs and GTs cannot pass in the human body but are hydrolyzed in the gastrointestinal tract to ellagic acid and gallic acid moieties [32–34]. Hydrolyzed ETs and GTs frequently gather in intestinal epithelial cells, where it not allowed to be absorbed into blood stream [35,36]. As a consequence,\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\ns reserved.\n37 lo 38 no 39 ab 40 pr 41 42 bi 43 di 44 ap 45 an 46 pr 47 m 48 as 49 ly 50 pr 51 ‘‘A 52 no 53 54 lim 55 [3 56 ca 57 su 58 bl 59 ha 60 61 po 62 th 63 w 64 pr 65 th 66 bi 67 va 68 op 69 ef 70 su 71 w 72 ph 73 tic 74 PE 75 re 76 m 77 ch 78 ef 79 dr 80 81 en 82 an 83 th 84 at 85 Th 86 el 87 PE 88 ce 89 lin\n90 2.\n91 2.\n92 93 In 94 m 95 po 96 de 97 fib 98 di 99 w\n100 101 102 103\n104\n105 106 107 108 109 110 111 112 113 114 115 116 117\n118\n119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141\n142\n143 144 145 146 147 148 149 150 151 152 153 154 155\n156 157 158\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx2\nw nanomolar levels of free ellagic acid and gallic acid have been ticed in circulation after ingestion [32,37]. Furthermore, sorbed ellagic acid and gallic acid have short half-life owing to ompt metabolism [38]. On the other hand, quercetin, a predominant ubiquitous oactive flavonoid, has been found to induce cell cycle arrest in fferent cancer cell lines [15]. It triggers caspases-mediated optosis resulted from the disruption of mitochondrial potential d cytochrome c release. Therefore, quercetin may be a ospective chemo-therapeutic agent in cancers [15,39] and can odulate some signaling cascades in some transduction pathways sociated with apoptosis (caspases 3, caspases 9, and B-cell mphoma 2 ‘‘Bcl-2’’), as well as cell survival (mitogen-activated otein kinase ‘‘MAPK’’ and protein kinase B ‘‘PKB’’, also known as kt’’) processes in acute myeloid leukemia, human hepatocarcima, and gastric cancer cells [40,41]. Cancer nanotechnology methods were primarily applied to it cytotoxicity, enhance bioavailability, and targetability 8]. More recently, these strategies are being subjugated in ncer inhibition with dietary phytochemicals [30,31,42]. Encaplation of these compounds into biodegradable and biocompatie nanoparticles may solve the problems of hydrolysis and short lf-life [38]. Due to the global ongoing interest in the nanotechnology with tential applications in health and drug delivery for cancer erapy [43,44], poly D-L-lactide-co-glycolide (PLGA) decorated ith chitosan (CS) and polyethylene glycol (PEG), PLGA-CS-PEG, ovides unique physicochemical characteristics resulting from e nano-size effect [45,46]. The nanoparticles of the FDA approved odegradable polymer, PLGA, is widely used for the delivery of rious natural treatments to the target site. However, rapid sonization by phagocytes is a major challenge for achieving fective drug targeting by PLGA nano-formulation [47]. Therefore, rface coating by biodegradable and biocompatible polymers ith low toxicity such as CS and PEG were used to curb the agocytic effects and to enhance the longevity of the nanoparles [48–50]. Intriguingly, the chemical modification of CS with G not only improves the biocompatibility of CS [51], but also duces the adsorption of circulating plasma proteins onto the aterial surface [52]. Consequently, a novel approach of nanoemoprevention, was born which holds promise to enrich the ficacy of bioactive phytochemical compounds through nanoug encapsulation [53]. In the present experimental setting, we hypothesized that capsulation of the bioactive compounds (quercetin, ellagic acid d gallic acid) in PLGA-CS-PEG nano-prototypes would increase eir anti-tumor activities through increased cellular uptake, tenuated hydrolysis, and sustained release in the cytoplasm. us, we designed, synthesized, and characterized quercetin, lagic acid, and gallic acid-loaded PLGA, PLGA-CS, and PLGA-CSG nanocomposites and examined their effects against hepatollular carcinoma (HepG2) and colorectal cancer (HCT 116) cell es in vitro.\nMaterials and methods\n1. Chemicals and reagents\nPoly (D,L-lactide-co-glycolide) (PLGA, copolymer ratio 50:50, herent viscosity 0.41) was purchased from (Birmingham polyers, Inc., Birmingham, AL). Quercetin, ellagic acid, gallic acid, lyvinyl alcohol (PVA, MW 30.000), chitosan (MW 60.90 kDa, gree of deacetylation 85%, derived from crab shells, in the form of rillar flakes), polyethylene glycol (2 kDa), and 3-(4,5- methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) ere purchased from Sigma–Aldrich Co., St. Louis, MO, USA.\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. C compounds: A novel approach for induction of apoptosis in H j.advms.2017.01.003\nAnnexin V and propidium iodide were purchased from ThermoFisher Scientific, UK. Ultrapure water (Millipore, Bedford, MA, USA) was used in the present study. All other chemicals were of analytical grade."
    }, {
      "heading" : "2.2. Preparation of PLGA nano-prototype",
      "text" : "PLGA nanocomposites were prepared by oil-in-water (O/W) single emulsion solvent evaporation method [46] with slight modifications. Briefly, 100 mg of PLGA polymer was dissolved in 3 ml of organic solvent (chloroform) to form a primary emulsion which was further emulsified in an aqueous PVA solution (12 ml, 2% w/v) to form an oil-in-water emulsion using a microtip probe sonicator (VC 505, Vibracell Sonics, Newton, USA) set at 55 W of energy output for 2 min over an ice bath. The emulsion was stirred overnight for the evaporation of the organic solvent. Excess amount of PVA was removed next day by ultracentrifugation at 50,602 g under cooling (4 8C) for 20 min (Sorvall Ultraspeed Centrifuge, Kendro, USA) followed by washing thrice with double distilled water."
    }, {
      "heading" : "2.3. Surface decoration of PLGA nano-prototype with CS and PEG",
      "text" : "To optimize the CS and PEG decoration, CS solution (12%, 20%, 25% w/w) was prepared in 1% glacial acetic acid and PEG formulations with different concentrations (5%, 10%, 20% w/w) and molecular weight (2 kDa, 6 kDa, 10 kDa) were added to the aqueous PVA before emulsification to get PLGA-CS-PEG nanoparticles. We observed through characterization of these formulations that the ratio of 12% CS and 5% PEG with 2 kDa molecular weight is the best one to formulate the PLGA-CS-PEG nanoparticles regarding to stability and nano-size ranges.\nFor the preparation of chitosan coated PLGA nanocomposite, a similar protocol was followed as mentioned earlier (preparation of PLGA nanoparticles), with slight modifications. Chitosan solution (12% w/w) was prepared in 1% glacial acetic acid, filtered and then added to the aqueous PVA solution prior to emulsification with the polymer to get chitosan coated PLGA (PLGA-CS) nanocomposite. Likewise, to study the effect of PEG, 5% w/w and molecular weight 2 kDa of PEG was added to the aqueous PVA and chitosan solution before emulsification to get PEG coated (PLGACS-PEG) nanocomposite.\nFor therapeutic applications, quercetin, ellagic acid, and gallic acid-loaded PLGA, PLGA-CS, and PLGA-CS-PEG nanocomposite were prepared in a similar way as mentioned above, by adding these compounds to the mixture prior emulsification."
    }, {
      "heading" : "2.4. Characterization of the nanocomposite",
      "text" : ""
    }, {
      "heading" : "2.4.1. Calibration curve and entrapment efficiency measurements",
      "text" : "Calibration curves were generated for quercetin, ellagic acid, and gallic acid using serial dilutions of each compound (0, 10, 20, 50, 100 mM). All data were equipped and processed with the microplate reader (BMG Labtech, Germany). The compound entrapment efficiency was calculated from the ratio of the compound amount incorporated into the nanocomposite to the total added compound amount. The prepared nanoformulations were enrolled to dialysis tubing technique for eliminating the impurities and the free non-conjugated compounds suspended in the solution by eluting it through regenerated cellulose (Amicon 10,000 MWCO ultra filter, Millipore, USA)."
    }, {
      "heading" : "2.4.2. Particle size and zeta potential analyses",
      "text" : "Mean particle size and zeta potential of the nanocomposites were determined by photon correlation spectroscopy (PCS)\nS-PEG decorated PLGA nano-prototype for delivery of bioactive epG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n159 160 161 162\n163 164 165 166 167 168 169 170 171 172 173\n174\n175 176 177 178 179 180 181 182 183 184 185 186 187\n188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211\n212 213 214 215 216 217 218 219\n220 221 222 223 224 225 226 227 228 229 230\n231\n232 233\n234\n235\n236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255\n256 257 258 259 260 261 262 263 264 265 266 267 268 269 270\n271 272 273 274 275 276 277 278\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx 3\nusing a Zeta Sizer (Nano ZS, Malvern Instruments, UK), All the samples were maintained at a constant temperature of 25.0 8C. Moreover, all experiments and each batch were analyzed in triplicates."
    }, {
      "heading" : "2.4.3. Drug release profile",
      "text" : "A certain amount of each PLGA-CS-PEG formula and its free drug were dispersed in a freshly prepared release medium in a dialysis bag (Mw cut-off 10 kDa; Millipore, USA). The enclosed dialysis bag was immersed in 30 ml of the release medium (pH 7.4) and placed in a shaking incubator at 37 8C under mild stirring. For each sample, one ml of the release medium was withdrawn at fixed time intervals and replaced by fresh medium. The collected media was filtered and the concentration of the released drug was measured using UV spectroscopy (Model 500; BIORed Instrument Inc., USA).\n2.5. In vitro assays"
    }, {
      "heading" : "2.5.1. HepG2 cancer cell propagation",
      "text" : "Human hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cells were purchased from American Type Culture Collection (ATCC). HepG2 and HCT 116 cells were propagated in the proper conditions (at 37 8C and 5% CO2) and maintained in Roswell Park Memorial Institute medium (RPMI1640) and Dulbecco Modified Eagle Medium (DMEM) with 1% Lglutamine (St Louis, MO, USA) and supplemented with 10% fetal calf serum for growth and 1% penicillin/streptomycin (Wexford, Ireland). When the cells are approximately 80% confluent, they were subcultured using trypsin–EDTA (Lonza, USA). Second round of the cancer cells subculturing was used for 96-well plates seeding and thereafter drug screening."
    }, {
      "heading" : "2.5.2. Growth inhibition assay",
      "text" : "The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT, Sigma) is based on the conversion of MTT into formazan crystals by living cells, which reflects cytotoxicity based on mitochondrial activity [54]. The cytotoxic impacts of the tested compounds and their nano-encapsulations were measured by MTT assay using HepG2 and HCT 116 cells. Briefly, the cells were cultured in 96-well plates at a density of 1 104 cells/well. The concentrations (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 mM) of the nano-formulations and their free counterparts were added per well in the media over the cancer cells. Also, media without drug was added as control. The zero point (0 mM) was used to represents cells without drugs only in case of free drugs (i.e. quercetin, ellagic acid, and gallic acid), but to represents cells treated with nano-void of each nano-drug (I added the same volume that I used for nano-formulations). After 24 h incubation, MTT dissolved in PBS was added to each well at a final concentration of 5 mg/ml, and the samples were incubated at 37 8C for 4 h. Water-insoluble crystals of formazan that formed during MTT cleavage in actively metabolizing cells were then dissolved in dimethyl sulfoxide (DMSO). Absorbance was measured at 455 nm, using a microplate reader (Model 500; BIORed Instrument Inc., USA). The mitochondrial activity (%) was calculated and compared with the control."
    }, {
      "heading" : "2.5.3. The half inhibitory concentration and fold change",
      "text" : "The half maximal inhibitory concentrations (IC50) values, the concentrations inhibit 50% of cell viabilities, were obtained by plotting the percentages of cell viabilities versus the concentrations of the sample using polynomial concentration–response curve fitting models (OriginPro 8 software). Finally, the fold changes of nano-formulations versus their free pure compounds were measured in HepG2 and HCT 116 cell lines.\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003"
    }, {
      "heading" : "2.5.4. Apoptotic assay",
      "text" : "Annexin V and propidium iodide (PI) were used for determination of HepG2 cell death mechanistic approach after treatments with 100 mM of nano-prototypes and their free counterparts at 24 h of drug incubation. HepG2 cells stained with only annexin V, only PI, or both dyes were considered as early apoptotic, necrotic or late apoptotic cells, respectively. Therefore, the apoptotic analysis was dedicated to differentiate between early and late apoptotic cells, as well as necrotic cells. The apoptosis of the treated and untreated HepG2 cells was analyzed by flow cytometer (Beckman Coulter Instrument, USA)."
    }, {
      "heading" : "2.6. Statistical analysis",
      "text" : "Comparisons between groups using SPSS: 23 were done via a ttest. P-values less than 0.05 were reflected significance."
    }, {
      "heading" : "3. Results",
      "text" : ""
    }, {
      "heading" : "3.1. Characterization and application of quercetin nano-prototypes",
      "text" : "For measuring the entrapment efficiency (EE) of quercetin in the nano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG), calibration curve (Fig. 1A) after dialysis tubing was performed. The results showed that the EE was approximately 70% of the initial concentration used in the nano-preparations. Quercetin-loaded PLGA, PLGA-CS, and PLGA-CS-PEG nanocomposites were characterized by Dynamic Light Scattering (DLS). DSL analysis showed that their Z-average diameters were around 255, 265, and 396 nm as illustrated minutely in Table 1 and Fig. 1B. The polydispersity index (PDI) was in the range of 0.1–0.2. There was a consistent pattern of negative charge (zeta potential) on the surface of quercetin-loaded PLGA, while positive charges (zeta potential) on the quercetin-loaded PLGA-CS and PLGA-CS-PEG nano-formulations (Table 1).\nAll nano-formulations were stable as shown in Table 1; where zeta potential and polydispersity index (PDI) of Q-PLGA-CS-PEG, E-PLGA-CS-PEG, G-PLGA-CS-PEG indicated that they are stable formulations. Zeta potential peaks as shown in the table are not close to zero and all PDI values were less than 0.5 would be enough to stabilize systems simply by electrostatic stabilization.\n3.1.1. In vitro quercetin release profile Since the main goal of this study is to develop stable PLGA-CSPEG nanoparticles against cancer treatment for an intravenous route of administration, the target site for drug release is the circulatory system. Therefore, the release profile of the prepared quercetin PLGA-CS-PEG formulation was evaluated in pH 7.4, similar to blood circulation pH. The release profile of our nanoformulation was compared with the dissolution rate of the free quercetin under similar conditions (Fig. 1C). The dissolution profile of free quercetin showed a rapid burst effect of about 100% in the first 1 h. On the other hand, the nano-formulation showed a gradually increase burst effect from 5% after 1 h to 57% after 24 h. These results demonstrated that the quercetin PLGA-CS-PEG reduces the burst release and provide a more controlled and sustained release of quercetin as compared to free quercetin."
    }, {
      "heading" : "3.1.2. Effect of quercetin nano-prototypes on HepG2 cell growth",
      "text" : "To determine whether nano-encapsulations ameliorate biological activity of the tested compounds, we compared the impact of quercetin versus its nano-prototypes (PLGA, PLGA-CS, and PLGACS-PEG) on HepG2 liver cancer cells in a wide dosage range from 0 to 100 mM. It was observed that all quercetin nano-prototypes induced HepG2 cell death by inhibiting cancer cell growth to a significantly greater extent than their free forms (Fig. 1D and\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n279 Ta 280 sh 281 co 282 ve 283 284 co 285 m 286 PL 287 va\n288 289 290 291 292 293 294 295 296\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx4\nble 2). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG nano-voids owed no remarkable impact on cell viability at the same ncentrations of nano-prototypes, indicating that these nanoctors are comparatively nontoxic. We measured the IC50, which is the half maximal inhibitory ncentration for HepG2 growth inhibition upon different treatents (Table 2). It was noticed that quercetin-encapsulated PLGA, GA-CS, and PLGA-CS-PEG nano-prototypes reduced the IC50 lues by 2.2, 2.9, and 2.8-folds, respectively (Table 2). These\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. C compounds: A novel approach for induction of apoptosis in H j.advms.2017.01.003\nresults indicate that these nano-delivery systems enhance the efficacy of this bioactive compound (quercetin). Furthermore, on comparison of the IC50s of the different three nano-prototypes of quercetin in terms of micromolarity, it was noticed that quercetinloaded PLGA-CS and PLGA-CS-PEG were more potent than PLGA on HepG2 cancer cell line. It was also recorded that quercetin itself had an undetectable IC50. Thus, we could suggest that CS and PEG improved the efficacy of quercetin in inhibiting liver cancer proliferation in vitro.\nS-PEG decorated PLGA nano-prototype for delivery of bioactive epG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312\n313 314 315 316 317 318 319 320 321 322\n323 324 325 326 327 328 329\n330\n331 332 333 334 335 336 337 338 339 340 341 342 343\n344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359\n360 361 362 363 364 365\nNotes: Mean SE for three determinations is shown. For particle size, Z-average is shown. Abbreviations: n, sample size; PDI, polydispersity index; SE, standard error.\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx 5"
    }, {
      "heading" : "3.1.3. Effects of quercetin nano-prototypes on HCT 116 cell growth",
      "text" : "To determine whether nano-encapsulations ameliorate biological activity of pomegranate phytochemicals, we compared the impact of quercetin versus its nano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG) in HCT 116 colorectal cancer cells in a wide dosage range from 0 to 100 mM. We observed that all pomegranate nano-prototypes induced HCT 116 cell death by inhibiting cancer cell growth to a significantly greater extent than their free forms (Fig. 1E). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG nano-voids had no remarkable impact on cell viability at the same concentrations of nano-prototypes, indicating that these nanovectors are comparatively nontoxic.\nWe measured the IC50, which is the half maximal inhibitory concentration for HCT 116 growth inhibition up on different treatments as showed in Table 2. We observed a bit the same cytotxic effects as that observed against HepG2 cells."
    }, {
      "heading" : "3.1.4. Quercetin nano-prototype induces HepG2 cancer cell apoptosis",
      "text" : "To test the mechanistic approach by which quercetin-loaded PLGA-CS-PEG nanocomposites attacked HepG2 cancer cells effectively, apoptosis was followed using flow cytometric technology. It was found that healthy cells were decreased upon 100 mM quercetin and its nano-prototype by 50.5% and 38.5%, respectively, after 24 h incubation, confirming their cytotoxic effects on HepG2 cells. The data of quercetin and its nano-form also reflect that the mechanistic approach of cancer cell death seems to be not only dependent on late apoptosis but also necrosis, where 7.5% and\nTable 2 Half maximal inhibitory concentration of cell growth (IC50s) of treatments and fold cha lines.\nTreatments HepG2 cells Fold\nQuercetin >100 Ref Quercetin-PLGA 43.87264 2.2 Quercetin-PLGA-CS 33.81113 2.9 Quercetin-PLGA-CS-PEG 34.69275 2.8 Ellagic >100 Ref Ellagic-PLGA >100 1 Ellagic-PLGA-CS 64.17965 1.5 Ellagic-PLGA-CS-PEG 36.86597 2.7 Gallic 69.17367 Ref Gallic-PLGA 72.33158 0.95 Gallic-PLGA-CS 93.76124 0.73 Gallic-PLGA-CS-PEG 43.43329 1.5\nNotes: Cells were treated for 24 h. Mean SE for three experiments is shown. Fold chan nanoprototype.\na represents P-value show statistically significant differences between mean IC50 of\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003\n8.4% of the control healthy population were shifted to the late apoptosis and necrosis quadrants, respectively, after quercetin therapy. Moreover, 17.2% and 22.7% of them were shifted in the late apoptosis and necrosis quadrants, respectively, after quercetin nano-prototype application. On the other hand, application of quercetin shifted the HepG2 cells to early apoptosis (33.5%) more than its nano-formulation (15.9%) (Fig. 1F and G)."
    }, {
      "heading" : "3.2. Characterization and application of ellagic acid nano-prototypes",
      "text" : "For measuring the EE of ellagic acid in the nano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG), calibration curve (Fig. 2A) after dialysis tubing was performed. It has been found that the EE was approximately 65% of the initial concentration used in the nano-prototypes. Ellagic acid-encapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nanoparticles were characterized by Dynamic Light Scattering (DLS). DSL analysis showed that their Z-average diameters were around 220, 220, and 255 nm as illustrated minutely in Table 1 and Fig. 2B. The polydispersity index (PDI) was up to 0.22. There was a consistent pattern of negative charge (zeta potential) on the surface of ellagic acid-encapsulated PLGA, while positive charges (zeta potential) on the ellagic acid-loaded PLGACS and PLGA-CS-PEG nano-prototypes (Table 1).\n3.2.1. In vitro ellagic acid release profile Since the main goal of this study is to develop stable PLGA-CSPEG nanoparticles against cancer treatment for an intravenous route of administration, the target site for drug release is the circulatory system. Therefore, the release profile of the prepared ellagic acid PLGA-CS-PEG formulation was evaluated in pH 7.4, similar to blood circulation pH. The release profile of our nanoformulation was compared with the dissolution rate of the free ellagic acid under similar conditions (Fig. 2C). The dissolution profile of free ellagic acid showed a rapid burst effect of about 100% in the first 1 h. On the other hand, the nano-formulation showed a gradually increase burst effect from 4% after 1 h to approximately 51% after 24 h. These results demonstrated that the ellagic acid PLGA-CS-PEG reduces the burst release and provide a more controlled and sustained release of ellagic acid as compared to free ellagic acid."
    }, {
      "heading" : "3.2.2. Effect of ellagic acid nano-prototypes on HepG2 cell growth",
      "text" : "To determine whether nano-encapsulations elevate the biological activity of ellagic acid, we compared the impact of ellagic acid free form versus its nano-prototypes (PLGA, PLGA-CS, and PLGA-CSPEG) on HepG2 liver cancer cells in a wide dosage range from 0 to 100 mM. It has been noticed that all ellagic acid nano-prototypes\nnge of nano-formulations versus their free counterparts on HepG2 and HCT 116 cell\nchange HCT 116 cells Fold change\n. 62.95075 Ref. 79325a 24.39697 2.578189a 57606a 21.32519 2.949563a 82447a 13.92073 4.518441a . 29.34482 Ref.\n13.09374 2.240765a\n58126a 9.47488 3.096609a 12529a 15.36478 1.909562a . 23.28298 Ref.\n6341 8.82931 2.636673a 7764 9.5243 2.444274a 92642a 15.29953 1.521615a\nge was calculated by dividing the IC50 of a free compound by that of the respective\npomegranate nanoprototypes and their free counterparts.\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n366 in 367 sig 368 Ta 369 ha 370 tio 371 re\n372 373 374 375 376 377\nFig. 2. Characterization and apoptosis-mediated cytotoxicity of ellagic acid-encapsulated PLGA-based nano-capsules. (A) Calibration curve of free Ellagic. (B) Nano-sizes of Ellagic-loaded PLGA, PLGA-CS, and PLGA-CS-PEG nanoparticles. (C) Drug release percentage of free ellagic acid and ellagic acid PLGA-CS-PEG nanoparticles. (D) Cytotoxic effects of a wide range of 0–100 mM free- and nano-formulations of Ellagic acid on HepG2 cells. (E) Cytotoxic effects of a wide range of 0–100 mM free- and nano-formulations of Ellagic acid on HCT 116 cells. (F) Flow cytometric analyses of HepG2 early and late apoptotic, as well as necrotic and healthy populations upon treatments with 100 mM of Ellagic-PLGA-CS-PEG and its free counterpart. (G) The mean and SE of three apoptosis-related flow cytometric experiments (n = 3). * represents significant differences between free- and nano-treatments points versus control or nano-void.\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx6\nduced HepG2 cell death by inhibiting cancer cell growth to a nificantly greater extent than their free forms (Fig. 2D and ble 2). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG nano-voids d no remarkable impact on cell viability at the same concentrans of nano-prototypes, indicating that these nano-vectors are latively non-cytotoxic.\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. C compounds: A novel approach for induction of apoptosis in H j.advms.2017.01.003\nWe measured the IC50 up on different treatments as showed in Table 2. It has been detected that ellagic acid-encapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes reduced the IC50 values by 1, 1.5, and 2.7-folds, respectively (Table 2). These outputs indicate that those nano-delivery systems enhance the efficacy of ellagic acid. Furthermore, we compared the IC50s of the different\nS-PEG decorated PLGA nano-prototype for delivery of bioactive epG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n378 379 380 381 382 383 384 385\n386 387 388 389 390 391 392 393\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx 7\nthree nano-prototypes of ellagic in terms of micromolarity. Our findings revealed that ellagic acid-loaded PLGA-CS-PEG (IC50 = 36.8 mM) then PLGA-CS (IC50 = 64.1 mM) were more potent than PLGA on HepG2 cancer cell line. It has been shown that ellagic acid-loaded PLGA nanocomposite and its free counterpart had undetectable IC50s. Thus, we would conclude that CS plus PEG improved the capability of ellagic acid in inhibiting liver cancer proliferation in vitro.\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003"
    }, {
      "heading" : "3.2.3. Effects of ellagic acid nano-prototypes on HCT 116 cell growth",
      "text" : "To determine whether nano-encapsulations ameliorate biological activity of pomegranate phytochemicals, we compared the impact of ellagic acid versus its nano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG) in HCT 116 cancer cells in a wide dosage range from 0 to 100 mM. We observed that all pomegranate nanoprototypes induced HCT 116 cell death by inhibiting cancer cell growth to a significantly greater extent than their free forms\n-based nano-capsules. (A) Calibration curve of free Gallic. (B) Nano-sizes of Gallic-\nree gallic acid and gallic acid PLGA-CS-PEG nanoparticles. (D) Cytotoxic effects of a ic effects of a wide range of 0–100 mM free- and nano-formulations of Gallic on HCT otic and healthy populations upon treatments with 100 mM of Gallic-PLGA-CS-PEG c experiments (n = 3). * represents significant differences between free- and nano-\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n394 (F 395 na 396 co 397 ve 398 399 ob 400 CS 401 Ta\n402 3. 403 ap 404 405 ap 406 us 407 10 408 87 409 th 410 na 411 ce 412 th 413 w 414 sh 415 af 416 sh 417 af 418 ap 419 (2 420 an\n421 3.\n422 423 (P 424 af 425 ap 426 pr 427 PE 428 (D 429 ar 430 an 431 co 432 su 433 (z 434 PE\n435 3. 436 437 PE 438 ro 439 ci 440 ga 441 sim 442 fo 443 ga 444 of 445 10 446 sh 447 af 448 ga 449 m 450 fre\n451 3. 452 453 ac 454 its\n455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476\n477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492\n493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509\n510\n511 512 513 514 515 516\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx8\nig. 2E and Table 2). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG no-voids had no remarkable impact on cell viability at the same ncentrations of nano-prototypes, indicating that these nanoctors are relatively non-cytotoxic. We measured the IC50 up on different treatments (Table 2). We served that ellagic acid-encapsulated PLGA, PLGA-CS, and PLGA-PEG nano-prototypes reduced the IC50 values as illustrated in ble 2 with effects quite similar to that against HepG2 cells.\n2.4. Ellagic acid nano-prototype induces HepG2 cancer cell\noptosis Flow cytometry was used to test the mechanistic cell death proach of ellagic acid-loaded PLGA-CS-PEG nanocomposite ing HepG2 cells. Healthy cell population decreased upon 0 mM treatment of ellagic acid and its nano-prototype by .1% and 30.4%, respectively, after 24 h. These results confirm eir cytotoxic effects on HepG2 cells. The data of ellagic acid nocomposites suggest that the mechanistic approach of cancer ll death seems to be dependent on early and late apoptosis. On e contrary, the free counterpart of ellagic acid induces necrosis, here 0.02% and 10.1% of the control healthy population were ifted to the late apoptosis and necrosis quadrants, respectively, ter ellagic acid therapy. Moreover, 16.1% and 7.4% of them were ifted in the late apoptosis and necrosis quadrants, respectively, ter ellagic acid nano-prototype application. On the opposite side, plication of ellagic acid shifted the HepG2 cells to early apoptosis .7%) remarkably less than its nano-formulation (45.9%) (Fig. 2F d G).\n3. Characterization and application of gallic acid nano-prototypes\nFor measuring the EE of gallic acid in the nano-prototypes LGA, PLGA-CS, and PLGA-CS-PEG), calibration curve (Fig. 3A) ter dialysis tubing was carried out. We found that the EE was proximately 80% of the total concentration used in the nanoototypes. Gallic acid-encapsulated PLGA, PLGA-CS, and PLGA-CSG nanoparticles were characterized by Dynamic Light Scattering LS). DSL analysis showed that their Z-average diameters were ound 164, 220, and 295 nm as represented minutely in Table 1 d Fig. 3B. The polydispersity index (PDI) was 0.1–0.2. There was a nsistent pattern of negative charge (zeta potential) on the rface of gallic acid-encapsulated PLGA, while positive charges eta potential) on the gallic acid-loaded PLGA-CS and PLGA-CSG nano-prototypes (Table 1).\n3.1. In vitro gallic acid release profile Since the main goal of this study is to develop stable PLGA-CSG nanoparticles against cancer treatment for an intravenous ute of administration, the target site for drug release is the rculatory system. Therefore, the release profile of the prepared llic acid PLGA-CS-PEG formulation was evaluated in pH 7.4,\nilar to blood circulation pH. The release profile of our nanormulation was compared with the dissolution rate of the free llic acid under similar conditions (Fig. 3C). The dissolution profile\nfree ellagic acid showed a rapid burst effect of approximately 0% in the first 1 h. On the other hand, the nano-formulation owed a gradually increase burst effect from approximately 4% ter 1 h to 43% after 24 h. These results demonstrated that the llic acid PLGA-CS-PEG reduces the burst release and provide a ore controlled and sustained release of gallic acid as compared to e gallic acid.\n3.2. Effect of gallic acid nano-prototypes on HepG2 cell growth\nTo elucidate whether nano-encapsulations enhance biological tivity of gallic acid, we compared the impact of gallic acid versus\nnano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG) in HepG2\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. C compounds: A novel approach for induction of apoptosis in H j.advms.2017.01.003\nliver cancer cells in a wide dosage range from 0 to 100 mM. Gallic acid nano-prototypes have been shown to induce HepG2 cell death by inhibiting cancer cell growth to a significantly greater extent than their free counterparts (Fig. 3D and Table 2). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG nano-voids had no remarkable impact on cell viability at the same concentrations of nano-prototypes, indicating that these nano-vectors are relatively non-cytotoxic.\nMeasurement of IC50 upon different treatments was done as showed in Table 2. The results revealed that there were no visible difference between gallic acid-encapsulated PLGA and PLGA-CS nano-prototypes and their free counterparts, except gallic acidloaded PLGA-CS-PEG nanocomposites which reduced the IC50 values by 1.5-fold (Table 2). These outputs indicate that only the PLGA-CS-PEG nano-delivery system enhances the efficacy of gallic acid. The comparison between the IC50s of the different three nano-prototypes of gallic in terms of micromolarity, suggested that gallic acid-loaded PLGA-CS-PEG (IC50 = 43.4 mM) followed by PLGA (IC50 = 72.3 mM) were more potent than PLGA-CS (IC50 = 93.7 mM) on HepG2 cancer cells. We noticed also that gallic acid had a detectable IC50 at 69.1 mM. Thus, we could conclude that CS plus PEG improved the efficacy of gallic acid in inhibiting liver cancer proliferation in vitro."
    }, {
      "heading" : "3.3.3. Effects of gallic acid nano-prototypes on HCT 116 cell growth",
      "text" : "To determine whether nano-encapsulations ameliorate biological activity of gallic acid, we compared the impact of gallic acid versus its nano-prototypes (PLGA, PLGA-CS, and PLGA-CS-PEG) in HCT 116 cancer cells in a wide dosage range from 0 to 100 mM. We observed that gallic acid nano-prototypes induced HCT 116 cell death by inhibiting cancer cell growth to a significantly greater extent than their free forms (Fig. 3E and Table 2). Moreover, PLGA, PLGA-CS, and PLGA-CS-PEG nano-voids had no remarkable impact on cell viability at the same concentrations of nano-prototypes, indicating that these nano-vectors are relatively non-cytotoxic.\nWe measured the IC50 up on different treatments as showed in Table 2. We observed that there were no visible difference between gallic acid-encapsulated PLGA and PLGA-CS nano-prototypes and their free counterparts, except gallic acid-loaded PLGA-CS-PEG nanoparticles as illustrated in (Table 2)."
    }, {
      "heading" : "3.3.4. Gallic acid nano-prototype induces HepG2 cancer cell apoptosis",
      "text" : "To explore the mechanistic approach by which gallic acidloaded PLGA-CS-PEG nanocomposite killed HepG2 cancer cells effectively, apoptosis was followed using flow cytometric technology. It was found that healthy cells were decreased up on 100 mM gallic acid and its nano-prototype by 62.2% and 48.6%, respectively, after 24 h incubation, confirming their cytotoxic effects on HepG2 cells. The data of gallic acid nanocomposites and its free counterpart indicate that cancer cell death seems to be dependent not only on early apoptosis not necrosis, where 0.3% and 5.5% of the control healthy population were shifted to the late apoptosis and necrosis quadrants, respectively, after gallic acid therapy. Moreover, 2.9% and 4.9% of them were shifted in the late apoptosis and necrosis quadrants, respectively, after gallic acid nano-prototype therapy. On the other hand, application of gallic acid shifted the HepG2 cells to early apoptosis (31.8%) remarkably less than its nano-formulation (43.4%) (Fig. 3F and G)."
    }, {
      "heading" : "4. Discussion",
      "text" : "In the current framework, we proposed three novel nanoprototypes of three compounds, namely quercetin, ellagic acid, and gallic acid, and assessed their killing impacts on HepG2 and HCT 116 cancer cells. We demonstrated that all the tested nanoencapsulations were greater in augmenting cell proliferation inhibition compared to their corresponding free counterparts in\nS-PEG decorated PLGA nano-prototype for delivery of bioactive epG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582\n583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630\n631\n632 633 634 635 636 637 638 639 640 641 642\n643\n644\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx 9\nboth cancer cell lines. Gallic acid was the most potent of those free counterparts and all PLGA-CS-PEG nano-formulations were superior in their anti-cancer activities. Nano-voids, which represented in figures as zero dose point, did not harm either HepG2 or HCT 116 cells at the same concentrations of nano-prototypes. These data are highly remarkable in cancer nano-targeting research. First, they suggest that PLGA-CS-PEG nanocomposites deliver a safe nano-approach to elevate the anti-tumor bioactivity of these compounds. Second, we have recognized a highly potent nano-platforms, namely PLGA-CS-PEG, for further tracking strategies in vivo models. Although ETs and GTs are principal polyphenols and quercetin is a predominant ubiquitous bioactive flavonoid, they have enormously low bioavailability [32,40,43]. Thus, PLGA-CS-PEG may be the nano-platform of choice for future nanochemoprevention investigations related to bioactive materials.\nQuercetin, a ubiquitous bioactive flavonoid, induces cell inhibition through apoptosis in a variety of cancer cell lines [40]. Alı́a et al. [55] mentioned that quercetin has an obviously cytotoxic effect on HepG2 cells and it causes up to 5-fold increase of LDH into the culture medium on HepG2. The high increase in the percent of LDH activity in the culture medium after treatment of HepG2 cells for 24 h with the highest doses of quercetin indicates a significant necrosis-mediated HepG2 cell death. In addition, the anti-carcinogenicity of quercetin includes inhibition cell proliferation by cell cycle arrest and induction of apoptosis [56–58]. These observations strongly confirm our current and previous results [15] indicating that quercetin formulations effectively induce HepG2 and HCT 116 cell death through both apoptosis and necrosis, as quercetin-encapsulated PLGA, PLGA-CS, and PLGA-CSPEG nano-prototypes reduced the IC50 values by 2.2, 2.9, 2.8-folds compared to their free counterparts. Intriguingly, our results were supported by Bishayee and his companions who disclosed that PLGA-loaded gold-nanoparticles precipitated with quercetin induce HepG2 cancer cell apoptosis through downregulation of HDAC-Akt, which in turn regulates cancer cell proliferation [59]. Depending on the MTT assay, we hypothesize that mitochondrion seems to be a crucial target for quercetin and this was supported by previous study demonstrated that quercetin induces mitochondrial dysfunction, causing a disruption in the mitochondrial membrane potential [60] and induction of apoptotic genes through suppression of NF-kB leads to an abrogation of proliferation which allows cells to come into the death pathways [61].\nThe present setting showed that ellagic acid formulations have significant cytotoxic effects on HepG2 and HCT 116 cell lines. This was supported by previous studies reported that ellagic acid, a type of polyphenols that widely exist in herbs, fruits, and nuts, exhibits anticancer [15,62] and antimutagenic [63] effects. The current work indicated that ellagic acid activates mitochondria-arbitrated apoptosis in HepG2 cancerous cells, which is in agreement with authors who suggested that the apoptotic caspase-3 expression was up-regulated and cell cycle arrest was induced in HepG2 cells following therapy with an ellagic acid derivative. Caspase-3 is elaborated in apoptosis persuaded by Bcl-2/Bax, p38 and Januskinase-signal transducer and activator of transcription (JAK-STAT) [7,64–66].\nGallic acid could inhibit cell proliferation, induce apoptosis, and inhibit transcription factors that endorse cell existence, and this comes in line with our results indicating that gallic acid formulations reduced the IC50 values by up to 1.5-fold through apoptosis. In addition, previous publication found that gallic acid could decrease colorectal cancer Caco-2 cell viability, arrest the cell cycle at G0/G1, and persuade apoptotic cell death. The stimulation of the apoptotic pathway by gallic acid was shown by the triggering of caspase-3 [67].\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003\nMost importantly, our observations indicated that CS-PEG blended PLGA nanocomposites were significantly more potent in inhibiting liver cancer cell proliferation than other nanocomposites, suggesting that this may be prime nano-platform for additional nanochemoprevention investigations with the tested nano-prototypes. This is in agreement with the recently published study postulated that PLGA-PEG-enabled intracellular delivery of punicalagin (PU), the pomegranate polyphenol which is hydrolyzed to ellagic acid moieties, would provide us with a potent anti-breast cancer nanochemoprevention. It was found that the PLGA–PEG nano-platform would protect PU from rapid hydrolysis, providing slow and sustained release of PU and other bioactive compounds into the breast cancer cells [53].\nThe current study suggested that drug delivery of quercetin, ellagic acid, and gallic acid encapsulated in PLGA-CS-PEG shuttle may provide a benefit over their free counterparts. In particular, these results are important in the light of previous positive [53] and negative [68] results. Li et al. [68] used partially purified ETs and gelatin to prepare nanoparticles and tested their cytotoxic impact on HL-60 leukemia cells. However, ETs-loaded gelatin nanoparticles were less effective than its free counterpart in cancer early apoptosis induction with no remarkable difference was noticed in late apoptosis. Insufficient nanoparticles uptake by HL60 leukemia cells was suggested as a believable reason for the lack of developed efficacy. In contrast to gelatin nanoparticles, PLGAbased nano-platforms have been shown to have outstanding cellular uptake both in vitro and in vivo [53,69], which confirms our data.\nIn this work, our study success is limited to cultured HepG2 and HCT 116 cancer cells. However, studies have investigated effectual delivery systems of bioactive phytochemicals through PLGA-based nanoparticles in vivo models [70–72]. Thereafter, we propose to settle our new strategy further in pre-clinical studies in vivo, where delivery of ETs and GTs are anticipated to defend against intestinal hydrolysis, increase absorption and systemic bioavailability, and extend their half-life via sustained release, cooperatively leading to improved protection against hepatocellular carcinoma. They may diminish cancer growth and progression due at least to their knowhow to inhibit cell development [9–15]. Due to ETs affect the cell viability of normal quiescent and postmitotic cells, they may retard progression of rapidly proliferating cells including pre-neoplastic and neoplastic cells (i.e. in early and advanced cancer stages), while sparing normal cells with only minor effects [53].\nOverall, the current study revealed that the prepared PLGA-CSPEG offers many advantages including controlled drug release through a decorated polymeric architecture and making it suitable for delivery of quercetin, gallic acid, and ellagic acid with improved bioavailability, which increased the anticancer potency."
    }, {
      "heading" : "5. Conclusion",
      "text" : "The present findings provide a clear evidence for the ability of that encapsulation of quercetin, ellagic acid, and gallic acid in PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes improve their bioefficacy against hepatocellular carcinoma HepG2 and HCT 116 cells in vitro. Furthermore, we branded PLGA-CS-PEG nanoprototype as the most potent of the three prototypes, suggesting that this nano-platform represents a formulation of choice for further data of natural nanocomposies. Further studies in establishing this new nanochemoprevention trend are warranted, touching the day when this new nano-approach tackles hepatocellular carcinoma globally.\nConflict of interest\nThe authors declare no conflict of interests.\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n645 Fi\n646 647 (1Q3\n648 Re\n649 [1 650 651 [2 652 653 [3 654 655 [4 656 657 658 [5 659 660 661 [6 662 663 664 [7 665 666 667 [8 668 669 [9 670 671 [10 672 673 674 [11 675 676 677 [12 678 679 [13 680 681 682 683 [14 684 685 686 [15 687 688 689 [16Q4 690 691 692 [17 693 694 695 [18 696 697 698 [19 699 700 701 [20 702 703 704 [21 705 706 707 [22 708 709 710 [23 711 712 713 714 [24 715 716 717 718 [25 719 720 721 [26 722 723 724 [27 725\n726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx10\nnancial disclosure\nThis research study was funded through the project number 0010106) which awarded by the National Research Center.\nferences\n] Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008;13(2):128–44. ] Johanningsmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. Annu Rev Food Sci Technol 2011;2:181–201. ] Heber D. Pomegranates: ancient roots to modern medicine. Boca Raton, FL: CRC Press; 2006. ] Heber D. Pomegranate ellagitannins. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. Boca Raton, FL: CRC Press; 2011. ] Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000;48(10):4581–9. ] Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 2003;42(1):18–28. ] Seeram N, Lee R, Hardy M, Heber D. Rapid large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry. Sep Purif Technol 2005;41(1):49–55. ] Larrosa M, Garcia-Conesa MT, Espin JC, Tomas-Barberan FA. Ellagitannins, ellagic acid and vascular health. Mol Aspects Med 2010;31(6):513–39. ] Syed DN, Afaq F, Mukhtar H. Pomegranate derived products for cancer chemoprevention. Semin Cancer Biol 2007;17(5):377–85. ] Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 2010;58(4):2180–7. ] Wang L, Alcon A, Yuan H, Ho J, Li QJ, Martins-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3(7):742–54. ] Adhami VM, Khan N, Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 2009;61(6):811–5. ] Shirode AB, Kovvuru P, Chittur SV, Henning SM, Heber D, Reliene R. Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks. Mol Carcinog 2014;53(6):458–70. ] Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006;54(3):980–5. ] Abd-Rabou AA, Shalby AB, Ahmed HH. Anti-cancer activity of quercetin, gallic acid, and ellagic acid against HepG2 and HCT 116 cell lines: in vitro. Int J Pharm Biol Sci 2016;7(4):B584–92. ] Albrecht M, Jiang W, Kumi-Diaka J, et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004;7(3):274–83. ] Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 2007;28(1):163–73. ] Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis 2012;33(3):644–51. ] Pantuck AJ, Leppert JT, Zomorodian N. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12(13):4018–26. ] Paller CJ, Ye X, Wozniak PJ, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013;16(1):50–5. ] Aqil F, Munagala R, Vadhanam MV, et al. Anti-proliferative activity and protection against oxidative DNA damage by punicalagin isolated from pomegranate husk. Food Res Int 2012;49(1):345–53. ] Khanduja KL, Gandhi RK, Pathania V, Syal N. Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 1999;37(4):313–8. ] Berni A, Grossi MR, Pepe G, et al. Protective effect of ellagic acid (EA) on micronucleus formation induced by N-methyl-N0-nitro-N-nitrosoguanidine (MNNG) in mammalian cells, in in vitro assays and in vivo. Mutat Res 2012;746(1):60–5. ] Anitha P, Priyadarsini RV, Kavitha K, Thiyagarajan P, Nagini S. Ellagic acid coordinately attenuates Wnt/beta-catenin and NF-kappaB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. Eur J Nutr 2013;52(1):75–84. ] Aiyer HS, Srinivasan C, Gupta RC. Dietary berries and ellagic acid diminish estrogen-mediated mammary tumorigenesis in ACI rats. Nutr Cancer 2008;60(2):227–34. ] Edderkaoui M, Odinokova I, Ohno I, et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol 2008;14(23):3672–80. ] Ho CC, Huang AC, Yu CS, et al. Ellagic acid induces apoptosis in tsgh8301 human bladder cancer cells through the endoplasmic reticulum stress- and\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. C compounds: A novel approach for induction of apoptosis in H j.advms.2017.01.003\nmitochondria-dependent signaling pathways. Environ Toxicol 2014;29(11): 1262–74. [28] Pitchakarn P, Chewonarin T, Ogawa K, et al. Ellagic acid inhibits migration and invasion by prostate cancer cell lines. Asian Pac J Cancer Prev 2013;14(5):2859–63. [29] Qiu Z, Zhou B, Jin L, et al. In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol 2013;59:428–37. [30] Abd-Rabou AA, Zoheir K, Ahmed HH. Potential impact of curcumin and taurine on human hepatoma cells using huh-7 cell line. Clin Biochem 2012;45:1519–21. [31] Ahmed HH, Abd-Rabou AA, Hassan AZ, Kotob SE. Phytochemical analysis and anti-cancer investigation of Bswellia serrata bioactive constituents in vitro. Asian Pac J Cancer Prev 2015;16(16):7179–88. [32] Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136(10):2481–5. [33] Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oakaged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 2005;53(2):227–35. [34] Cerda B, Espin JC, Parra S, Martinez P, Tomas-Barberan FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 2004;43(4): 205–20. [35] Smart RC, Huang MT, Chang RL, Sayer JM, Jerina DM, Conney AH. Disposition of the naturally occurring antimutagenic plant phenol, ellagic acid, and its synthetic derivatives, 3-O-decylellagic acid and 3,30-di-O-methylellagic acid in mice. Carcinogenesis 1986;7(10):1663–7. [36] Whitley AC, Stoner GD, Darby MV, Walle T. Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid – extensive binding to protein and DNA. Biochem Pharmacol 2003;66(6):907–15. [37] Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 2004;348(1–2):63–8. [38] Bharali DJ, Siddiqui IA, Adhami VM, et al. Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers 2011;2011(3):4024–45. [39] Seufi AEM, Ibrahim SS, Elmaghraby TK, Hafez EE. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J Exp Clin Cancer Res 2009;28:80. [40] Kaneuchi M, Sasaki M, Tanaka Y, Sakuragi N, Fujimoto S, Dahiya R. Quercetin regulates growth of Ishikawa cells through the suppression of EGF and cyclin D1. Int J Oncol 2003;22:159–64. [41] Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L, Lin C. Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci 2005;76:1883–93. [42] Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett 2013;334(1):142–51. [43] Shoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanotechnology 2007;3:20–31. [44] Park JH, Lee S, Kim JH, et al. Polymeric nanomedicine for cancer therapy. Prog Polym Sci 2008;33:113–37. [45] Sumer B, Gao J. Therapeutic nanomedicine for cancer. Nanomedicine 2008;3:137–40. [46] Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol 2011;670:372–83. [47] Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Delivery Rev 1995;16:215–33. [48] Hu FQ, Meng P, Dai YQ, Du YZ, You J, Wei XH, et al. PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy. Eur J Pharm Biopharm 2008;70:749–57. [49] Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998;15:1326–31. [50] Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Q5Enhanced antiproliferative activity of carboplatin-loaded chitosan–alginate nanoparticles in a retinoblastoma cell line. Acta Biomater 2010;6:3120–31. [51] Zhang M, Li XH, Gong YD, Zhao NM, Zhang XF. Properties and biocompatibility of chitosan films modified by blending with PEG. Biomaterials 2002;23:2641–8. [52] Amiji MM. Synthesis of anionic poly (ethylene glycol) derivative for chitosan surface modification in blood-contacting applications. Carbohydr Polym 1997;32:193–9. [53] Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R. Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. Int J Nanomed 2015;10:475–84. [54] van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011;731:237–45. [55] Alı́a M, Mateos R, Ramos S, Lecumberri E, Bravo L, Goya L. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). Eur J Nutr 2006;45:19–28. [56] Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001;90(2–3):157–77.\nS-PEG decorated PLGA nano-prototype for delivery of bioactive epG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/\n812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837\n838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863\nA.A. Abd-Rabou, H.H. Ahmed / Advances in Medical Sciences xxx (2017) xxx–xxx 11\n[57] Nichenametla SN, Taruscio TG, Barney DL, Exon JH. A review of the effects and mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 2006;46(2): 161–83. [58] Balan KV, Prince J, Han Z, Dimas K, Cladaras M, Wyche JH, et al. Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia. Phytomedicine 2007;14:263–72. [59] Bishayee k, Khuda-Bukhsh AR, Huh S. PLGA-loaded gold-nanoparticles precipitated with quercetin downregulate hdac-akt activities controlling proliferation and activate p53-ros crosstalk to induce apoptosis in hepatocarcinoma cells. Mol Cells 2015;38(6):518–27. [60] Lugli E, Ferraresi R, Roat E, Troiano L, Pinti M, Nasi M, et al. Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leuk Res 2009;33:140–50. [61] Nakanishi C, Toi M. Nuclear factor NF-kB inhibitors, as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297–309. [62] Maas JL, Galletta GJ. Ellagic acid, an anticarcinogen in fruits, especially in strawberries: a review. Hortscience 1991;26:10–4. [63] Thresiamma KC, George J, Kuttan R. Protective effect of curcumin, ellagic acid and bixin on radiation induced genotoxicity. J Exp Clin Cancer Res 1998;17:431–4. [64] Zhang H, Guo ZJ, XU WM, YOU XJ, Han L, HAN YX, et al. Antitumor effect and mechanism of an ellagic acid derivative on the HepG2 human hepatocellular carcinoma cell line. Oncol Lett 2014;7:525–30. [65] Dassé E, Bridoux L, Baranek T, Lambert E, Salesse S, Sowa ML, et al. Tissue inhibitor of metalloproteinase-1 promotes hematopoietic differentiation via\nPlease cite this article in press as: Abd-Rabou AA, Ahmed HH. CS compounds: A novel approach for induction of apoptosis in He j.advms.2017.01.003\ncaspase-3 upstream the MEKK1/MEK6/p38alpha pathway. Leukemia 2007; 21:595–603. [66] Mertens-Talcott SU, Talcott ST, Percival SS. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis 9 in MOLT-4 human leukemia cells. J Nutr 2003;133: 2669–74. [67] Forester SC, Choy YY, Waterhouse AL, Oteiza PI. The anthocyanin metabolites gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde decrease human colon cancer cell viability by regulating pro-oncogenic signals. Mol Carcinog 2014;53(6):432–9. [68] Li Z, Percival SS, Bonard S, Gu L. Fabrication of nanoparticles using partially purified pomegranate ellagitannins and gelatin and their apoptotic effects. Mol Nutr Food Res 2011;55(7):1096–103. [69] Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) 2013;8(12):1943–54. [70] Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009;69(5): 1712–6. [71] Xie X, Tao Q, Zou Y. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 2011;59(17):9280–9. [72] Khalil NM, do Nascimento TC, Casa DM. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 2013;101:353–60.\n-PEG decorated PLGA nano-prototype for delivery of bioactive pG2 cell line. Adv Med Sci (2017), http://dx.doi.org/10.1016/"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2017,
    "abstractText" : "Purpose: Polymer-based nanoparticles are used as vectors for cancer drug delivery. The bioactive compounds (quercetin, ellagic acid and gallic acid) are well known to be not only antioxidants but also chemopreventive candidates against various types of cancers. To circumvent the low bioavailability and the short half-life time obstacles, we hypothesized a novel PLGA nano-platform functionalized with CS and PEG to encapsulate these phytochemicals. This encapsulation will protect the compounds from the phagocytic uptake and deliver PLGA-CS-PEG nano-prototype with high biodegradability and biosafety. Materials and methods: Three consequent types of PLGA-based nanocomposites were prepared and characterized. Furthermore, we investigated the newly synthesized nano-formulations against human hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cell lines using cell growth inhibition assays, followed by apoptosis and necrosis assays using flow cytometry to detect the underlying mechanism of HepG2 cell death. Results: Through Malvern Zeta Sizer, we recorded that the average diameters of the nano-prototypes ranged from 150 to 300 nm. Regarding the cytotoxic activity of quercetin, ellagic acid, and gallic acidencapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes has been found that they reduce the IC50s of the HepG2 cells values by 2.2, 2.9, 2.8-folds, 1, 1.5, 2.7-folds, and 0.9, 0.7, 1.5-folds, respectively. Mechanistically, the nano-platforms of quercetin seem to be dependent on both apoptosis and necrosis, while those of ellagic acid and gallic acid are mainly dependent on apoptosis. Conclusions: CS-PEG-blended PLGA nano-delivery system of quercetin, ellagic acid and gallic acid can potentiate apoptosis-mediated cell death in HepG2 cell line. 2017 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.",
    "creator" : "Elsevier"
  }
}